Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Aviceda Ophthalmics is raising $26,200,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mohamed Genead played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aviceda Ophthalmics
Aviceda Therapeutics is an IND-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, oncologic, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Avicedas engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Avicedas platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.

To learn more about Aviceda Ophthalmics, visit http://www.avicedarx.com/

Contact:
Mohamed Genead, Chief Executive Officer
617-332-0741
mgenead@avicedarx.com
https://www.linkedin.com/in/mohamedgeneadmd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved